ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal modelComplete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-.
Share this article
Share this article
Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal
Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the nose and throat by up to 96%; also found to be effective against rhinovirus (common cold), the
predominant cause of the common cold and exacerbations of chronic respiratory diseases including asthma and COPD
Mode of action complementary to COVID-19 vaccines, once weekly nasal spray to play significant role in reducing COVID-19 community transmission and disease progression in at risk populations
Atlas Advisors Australia and Uniseed increase stake in Ena Respiratory miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.